Poseida Therapeutics (NASDAQ:PSTX) Receives Overweight Rating from Cantor Fitzgerald

Poseida Therapeutics (NASDAQ:PSTXGet Rating)‘s stock had its “overweight” rating reaffirmed by Cantor Fitzgerald in a report released on Monday, Zacks.com reports. Cantor Fitzgerald also issued estimates for Poseida Therapeutics’ FY2022 earnings at ($3.02) EPS.

Separately, Zacks Investment Research downgraded shares of Poseida Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, March 10th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $21.75.

Shares of PSTX stock opened at $1.87 on Monday. Poseida Therapeutics has a 12 month low of $1.84 and a 12 month high of $11.10. The company has a quick ratio of 4.94, a current ratio of 4.94 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $3.83 and its two-hundred day moving average is $5.17. The company has a market cap of $116.96 million, a PE ratio of -0.93 and a beta of 1.00.

Poseida Therapeutics (NASDAQ:PSTXGet Rating) last announced its quarterly earnings data on Thursday, March 10th. The company reported $0.02 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.36. The company had revenue of $31.24 million during the quarter, compared to analyst estimates of $23.75 million. As a group, equities analysts expect that Poseida Therapeutics will post -2.62 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in Poseida Therapeutics by 7.0% during the first quarter. JPMorgan Chase & Co. now owns 318,676 shares of the company’s stock worth $1,428,000 after buying an additional 20,894 shares in the last quarter. Forefront Analytics LLC boosted its stake in Poseida Therapeutics by 152.1% during the first quarter. Forefront Analytics LLC now owns 26,770 shares of the company’s stock worth $121,000 after buying an additional 16,150 shares in the last quarter. MCF Advisors LLC acquired a new stake in Poseida Therapeutics during the first quarter worth $257,000. Nisa Investment Advisors LLC acquired a new stake in Poseida Therapeutics during the first quarter worth $58,000. Finally, BlackRock Inc. boosted its stake in Poseida Therapeutics by 0.8% during the fourth quarter. BlackRock Inc. now owns 2,552,990 shares of the company’s stock worth $17,385,000 after buying an additional 19,851 shares in the last quarter. Hedge funds and other institutional investors own 41.89% of the company’s stock.

Poseida Therapeutics Company Profile (Get Rating)

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).

Read More

Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.